Physician profile
Claude Su
NPI 1437122983
$4,592.00
in general payments reported to CMS, 2019-2025
24 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $447 · 2021: $342 · 2022: $753 · 2023: $1,064 · 2024: $990 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,516.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $697.07 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $685.19 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $635.82 | 2019-2025 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $433.22 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $398.25 | 2019-2024 | Xarelto |
| Amgen INC. | $300.81 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $287.47 | 2019-2025 | |
| Cvrx, INC. | $152.37 | 2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $136.88 | 2023-2024 | Inpefa |
| Abbott Laboratories | $125.60 | 2019-2024 | Jot Dx, Aveir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.00 | 2023-2025 | Jardiance |
| Astellas Pharma US INC | $99.00 | 2020 | |
| Merck Sharp & Dohme LLC | $79.80 | 2022-2023 | Verquvo |
| Philips North America LLC | $77.87 | 2020-2022 | |
| Biotronik INC. | $64.99 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $59.92 | 2019-2025 | Watchman Flx |
| Esperion Therapeutics, INC. | $58.64 | 2022-2024 | Nexletol |
| Baxter Healthcare | $36.34 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Kiniksa Pharmaceuticals, LTD. | $34.63 | 2022-2023 | Arcalyst |
| Abiomed | $34.01 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.68 | 2021 | |
| Inspire Medical Systems, INC. | $21.33 | 2025 | Inspire |
| Cardiovascular Systems INC. | $19.04 | 2023 | Diamondback Coronary |
| Acist Medical Systems, INC. | $16.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claude Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.